However, recent studies have shown that even in the absence of fusion proteins, RUNX1 acts as an oncogene by cooperating with BCR-ABL to induce blast crisis phase like phenotype in CML cases [7]. Here, RUNX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.